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Objective/background: Ethionamide (ETH) and isoniazid (INH) are part of the backbone regi-
men used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Both ETH and
INH are structurally similar and are activated by ethA and katG gene products. Resistance
to INH among MDR-TB patients may cause ETH to be ineffective, as both target nicoti-
namide adenine dinucleotide-dependent enoyl-acyl carrier protein reductase inhA protein
andmutations within inhA genemay lead to their cross-resistance. Furthermore, ETH resis-
tance is caused by mutations within ethA and ethR genes forming part of the ETH drug acti-
vation pathway. Nicotinamide adenine dinucleotide is coded by the ndh gene, and its
overexpresion may lead cross-resistance between INH and ETH drugs. Phenotypic drug
susceptibility testing of ETH is difficult and often unreliable. We used whole genome
sequencing to compare inhA, inhA promoter, ethA, ethR ndh, and katG genetic regions in
serial isolates (baseline and follow-up) with treatment outcomes.
Methods: MDR-TB strains were collected from 46 patients before and during second-line
drug treatment in KwaZulu-Natal and Eastern Cape between 2005 and 2009. All patients
had phenotypically determined MDR-TB at baseline and had treatment outcomes docu-
mented. Unfavorable treatment outcomes were defined as death, default, and failure, while
favorable outcomes were cure and treatment completion. Each strain had baseline and at
least one strain collected on follow-up. From each strain, DNAwas extracted from colonies
grown on Lo¨wenstein–Jensen slants, and fragment and jumping paired-end Illumina DNA
libraries were constructed and sequenced on the Illumina HiSeq 2000 (Broad Institute,
Cambridge, MA, USA). Sequences were aligned to H37Rv genome and Pilon was run to gen-
erate a list of SNPs. In silico spoligotyping was performed to a database 43 unique spacer
sequences. Cross-resistance was defined as the presence of both inhA and either ethA or
ethR mutations in clinical isolates.
Results: A total of 92 sequences from 46 serial isolates of MDR-TB patients from KwaZulu-
Natal (29 isolates) and Eastern Cape (17 isolates) were analyzed. Most patients (29/46; 63.0%)n with poor
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treatment outcomes of multidrug-resistant tuberculoshad unfavorable outcomes, 13 (28.3%) had favorable outcomes, while four (8.7%) had
unknown outcomes. Phylogenetic reconstruction revealed that primary genotype differed
by province. The Beijing genotype was predominant in Eastern Cape, while EuroAmerican
lineage (S, T, LAM, X) was found in KwaZulu-Natal. Whole genome analysis revealed non-
synonymous insertions and deletions within katG, ethA, ethR, ndh, and inhA and its pro-
moter region. Among patients with treatment outcome data, mutations were detected in
92.8% in katG, 50% in inhA, 53.6% in ethA, 2.4% in ethR, and 19% in ndh. The majority of
mutations causing ETH (20/29; 68.9%) and INH (18/29; 62.1%) resistance occurred among
patients with unfavorable outcomes. Both inhA and either ethA or ethR mutations were
detected in 16/29 (55.2%) patients with unfavorable outcomes. Cross-resistance of both
INH and ETH drugs was associated with unfavorable treatment outcomes (p = 0.021) in
16/29 (55.2%) patients compared with favorable treatment outcomes in 2/13 (15.4%)
patients.
Conclusion: Baseline ETH molecular resistance before second-line treatment is a concern.
Unfavorable treatment outcomes of patients with ethA, ethR, and inhA mutations highlight
the importance of genotypic testing before initiation of treatment containing ETH. The clin-
ical significance of whole genome analysis for early detection of mutations predictive of
treatment failure needs further investigation.Conflicts of interest
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